Interpace Biosciences Stock Earnings Per Share
Interpace Biosciences fundamentals help investors to digest information that contributes to Interpace Biosciences' financial success or failures. It also enables traders to predict the movement of Interpace OTC Stock. The fundamental analysis module provides a way to measure Interpace Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Interpace Biosciences otc stock.
Interpace |
Interpace Biosciences OTC Stock Earnings Per Share Analysis
Interpace Biosciences' Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Current Interpace Biosciences Earnings Per Share | (3.12) X |
Most of Interpace Biosciences' fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Interpace Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
CompetitionAccording to the company disclosure, Interpace Biosciences has an Earnings Per Share of -3.117 times. This is 137.24% lower than that of the Health Care Providers & Services sector and notably lower than that of the Health Care industry. The earnings per share for all United States stocks is 199.9% higher than that of the company.
Interpace Earnings Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Interpace Biosciences' direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Interpace Biosciences could also be used in its relative valuation, which is a method of valuing Interpace Biosciences by comparing valuation metrics of similar companies.Interpace Biosciences is currently under evaluation in earnings per share category among its peers.
Interpace Fundamentals
| Return On Equity | -2.85 | ||||
| Return On Asset | -0.26 | ||||
| Profit Margin | (0.59) % | ||||
| Operating Margin | (0.28) % | ||||
| Current Valuation | 11.72 M | ||||
| Shares Outstanding | 4.27 M | ||||
| Shares Owned By Insiders | 28.12 % | ||||
| Number Of Shares Shorted | 47.35 K | ||||
| Price To Earning | (1.07) X | ||||
| Price To Book | 10.04 X | ||||
| Price To Sales | 0.10 X | ||||
| Revenue | 41.31 M | ||||
| Gross Profit | 17.95 M | ||||
| EBITDA | (9.12 M) | ||||
| Net Income | (14.94 M) | ||||
| Cash And Equivalents | 1.86 M | ||||
| Cash Per Share | 0.44 X | ||||
| Total Debt | 9.44 M | ||||
| Debt To Equity | 6.55 % | ||||
| Current Ratio | 0.61 X | ||||
| Book Value Per Share | (14.51) X | ||||
| Cash Flow From Operations | (8.72 M) | ||||
| Short Ratio | 0.19 X | ||||
| Earnings Per Share | (3.12) X | ||||
| Target Price | 11.0 | ||||
| Number Of Employees | 147 | ||||
| Beta | 0.82 | ||||
| Market Capitalization | 5.16 M | ||||
| Total Asset | 38.43 M | ||||
| Retained Earnings | (172.59 M) | ||||
| Working Capital | (4.21 M) | ||||
| Current Asset | 19.16 M | ||||
| Current Liabilities | 23.37 M | ||||
| Z Score | -4.6 | ||||
| Net Asset | 38.43 M |
Currently Active Assets on Macroaxis
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Other Consideration for investing in Interpace OTC Stock
If you are still planning to invest in Interpace Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Interpace Biosciences' history and understand the potential risks before investing.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |